[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100499481":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":41,"centralContacts":45,"locations":51,"responsibleParty":69,"collaborators":40,"id":73,"slug":74,"hasResults":75,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":75,"sex":81,"minAge":82,"maxAge":40,"enrollmentInfo":83,"targetDuration":40,"studyType":86,"phases":87,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":54,"whyStopped":40,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"Stanford University","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"MDMA-assisted cognitive behavioral therapy","EXPERIMENTAL","Administration of 80mg MDMA HCl (with a supplemental dose offered 1.5 to 2 hours later of 40 mg MDMA HCl) in combination with cognitive behavioral therapy (CBT).",[13,14],"Drug: 3,4-Methyl enedioxy methamphetamine","Behavioral: Cognitive Behavioral Therapy (CBT)",{"label":16,"type":17,"description":18,"interventionNames":19},"Methamphetamine-assisted cognitive behavioral therapy","ACTIVE_COMPARATOR","Administration of 10mg methamphetamine (with a supplemental dose offered 1.5 to 2 hours later of 5 mg methamphetamine) in combination with cognitive behavioral therapy (CBT).",[20,14],"Drug: Methamphetamine",[22,29,35],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"DRUG","3,4-Methyl enedioxy methamphetamine","MDMA (3,4 methylenedioxymethamphetamine) is a synthetic, psychoactive drug that is chemically similar to the stimulant methamphetamine.",[9],[28],"MDMA",{"type":23,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"Methamphetamine","Methamphetamine is a stimulant that affects the central nervous system. This is used as a control in the study.",[16],[34],"MA",{"type":36,"name":37,"description":38,"armGroupLabels":39,"otherNames":40},"BEHAVIORAL","Cognitive Behavioral Therapy (CBT)","Cognitive Behavioral Therapy with exposure and response prevention performed by therapist team.",[9,16],null,[42],{"name":43,"affiliation":5,"role":44},"Carolyn Rodriguez, MD, PhD","PRINCIPAL_INVESTIGATOR",[46],{"name":47,"role":48,"phone":49,"phoneExt":40,"email":50},"Alessa Gaeta, MS","CONTACT","650-723-4095","ocdresearch@stanford.edu",[52],{"facility":53,"status":54,"city":55,"state":56,"zip":57,"country":58,"countryCode":59,"cosmosGeoPoint":60,"geoPoint":65,"contacts":66},"Stanford University Medical Center","RECRUITING","Palo Alto","California","94305","United States","US",{"type":61,"coordinates":62},"Point",[63,64],-122.14302,37.44188,{"lat":64,"lon":63},[67],{"name":68,"role":48,"phone":49,"phoneExt":40,"email":50},"Alessa Gaeta, BS",{"type":70,"investigatorFullName":71,"investigatorTitle":72,"investigatorAffiliation":5,"oldNameTitle":40,"oldOrganization":40},"SPONSOR_INVESTIGATOR","Carolyn Rodriguez","Professor","100499481","phase-2-mdma-assisted-cbt-for-ocd-mdma-cbt4ocd-study-100499481",false,"NCT05783817","MDMA-Assisted CBT for OCD (MDMA-CBT4OCD Study)","MDMA-Assisted Cognitive Behavioral Therapy (CBT) Compared With Methamphetamine-Assisted CBT in Obsessive-Compulsive Disorder (OCD): A Phase II Study","MDMA-CBT4OCD","Inclusion Criteria:\n\n1. At least 18 years old\n2. Fluent in speaking and reading the predominantly used or recognized language of the study site\n3. Able to swallow pills\n4. Meet the criteria for OCD diagnosis\n5. YBOCS total score of at least 16\n6. Not on psychotropic medications 1 month prior to study enrollment\n7. Able to tolerate a treatment-free period\n8. Able to tolerate study procedures\n9. Failed at least 1 prior trial of standard first-line OCD treatment\n10. Agree to the following lifestyle modifications: comply with requirements for fasting and refraining from certain medications prior to the Experimental Session, not enroll in any other interventional clinical trials during the duration of the study, and commit to medication dosing, therapy, and study procedures.\n\nExclusion Criteria:\n\n1. Pregnant or nursing, or able to become pregnant and are not practicing an effective means of birth control\n2. Weigh less than 48 kilograms (kgs)\n3. Any current problem which, in the opinion of the investigator or study physician, might interfere with participation","ALL","18 Years",{"count":84,"type":85},40,"ESTIMATED","INTERVENTIONAL",[88],"PHASE2","The study assesses the safety and preliminary effectiveness of MDMA-assisted cognitive behavioral therapy in participants diagnosed with obsessive-compulsive disorder (OCD).",[91],"Obsessive-Compulsive Disorder",[93,28,94,95],"OCD","OCD CBT","Cognitive Behavioral Therapy","2026-03-03",{"date":98,"type":99},"2026-03-05","ACTUAL",{"date":101,"type":99},"2025-09-10",{"date":103,"type":85},"2026-12-01",{"name":71,"class":6},1]